

OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person * <u>McCarthy Christopher</u> (Last) (First) (Middle) <u>C/O INTERPACE BIOSCIENCES, INC.</u> <u>2001 ROUTE 46 WATERVIEW PLAZA, SUITE 310</u> (Street) <u>PARSIPPANY NJ 07054</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>INTERPACE BIOSCIENCES, INC. [IDXX]</u> 3. Date of Earliest Transaction (Month/Day/Year) <u>08/20/2026</u> 4. If Amendment, Date of Original Filed (Month/Day/Year)	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) <u>CFO & COO</u> 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
--	---	---

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/20/2026		M		277,009 ⁽¹⁾	A	\$0	323,800	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	(2)	08/20/2026		A		554,018		(3)	(3)	Common Stock	554,018	\$0	554,018	D	
Restricted Stock Units	(2)	08/20/2026		M			277,009	(3)	(3)	Common Stock	277,009	\$0	277,009	D	
Stock Option (right to buy)	\$2.02	08/20/2026		A		277,009		(4)	08/20/2036	Common Stock	277,009	\$0	277,009	D	

Explanation of Responses:

1. Represents the conversion upon vesting of restricted stock units (RSUs) into shares of common stock of Interpace Biosciences, Inc. On August 20, 2026, the Reporting Person was granted 554,018 RSUs, of which 277,009 vested upon grant and 277,009 will vest on August 20, 2027, subject to the Reporting Person's continued service on such vesting date.
2. Each RSU represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc.
3. On August 20, 2026, the Reporting Person was granted 554,018 RSUs, of which 277,009 vested upon grant and 277,009 will vest on August 20, 2027, subject to the Reporting Person's continued service on such vesting date.
4. The options will vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date.

/s/ Christopher McCarthy 08/20/2026
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.